摘要
研究背景和目标:抑制热休克蛋白HSP90是治疗胰腺癌(PC)的潜在战略,因为许多HSP90客户蛋白在PC中过表达或发生突变。而这些客户蛋白直接参与调节PC的扩增和加剧。我们前期的研究发现Y306zh是潜在的新颖的HSP90抑制剂,这项研究中我们更进一步探索Y306zh作为抗PC药物的作用机制。 材料和方法:通过荧光偏振法分析Y306zh对HSP90的结合亲和力。使用人类PC细胞株和Miapaca2胰腺癌异种移植模型研究Y306zh的抗增殖活性和分子机制。 结果:Y306zh与HSP90的氨基末端结合紧密,IC50为85 nM,这导致了ATP不能再与相同位点结合,并影响HSP90-p23复合体形成。Y306zh也能诱导HSP70的表达,聚集形成CHIP、 HSP70和 HSP90复合体,并通过蛋白酶体途径最终导致HSP90客户蛋白(EGFR, AKT, C-RAF and CDK4)的降解。令人惊讶的是,与分子机理一致,Y306zh通过对细胞G2/M期阻滞抑制PC细胞增殖,但对正常的哺乳动物细胞完全不敏感。而且Y306zh有效抑制Miapaca2胰腺癌异种移植小鼠的肿瘤生长而不明显影响小鼠体重。 结论:Y306zh,是一种新型的HSP90抑制剂,能中断ATP结合至HSP90从而扰乱HSP90-p23的相互作用,并最终抑制胰腺癌细胞的生长。
关键词: 分子伴侣复合体,客户蛋白,热休克蛋白90,胰腺癌,p23
图形摘要
Current Cancer Drug Targets
Title:Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways
Volume: 14 Issue: 7
Author(s): Nina Xue, Jing Jin, Di Liu, Rui Yan, Sen Zhang, Xiaoming Yu and Xiaoguang Chen
Affiliation:
关键词: 分子伴侣复合体,客户蛋白,热休克蛋白90,胰腺癌,p23
摘要: Background and Aim: Inhibition of HSP90 is a potential strategy to treat pancreatic cancer (PC), since many client proteins of HSP90 are found to be over-expressed and/or genetically mutated in PC. These client proteins directly participate in the modulation of proliferation and aggravation of PC. Our previous works led to Y306zh as a novel and potent HSP90 inhibitor. In this study we further investigated the mode of actions of Y306zh as an anti-PC agent.
Materials and Methods: The binding affinity of Y306zh towards HSP90 was analyzed by fluorescence polarization assay. The anti-proliferative activities and molecular mechanism of Y306zh were investigated in human PC cell lines and Miapaca2 xenograft model.
Results: Y306zh binds tightly to the NH2-terminus of HSP90 with an IC50 of 85 nM, and this causes ATP incapable to attach to the same binding site, and disrupts HSP90-p23 association. Y306zh also induces the expression of HSP70, recruits the complex of CHIP, HSP70 and HSP90, and eventually results in the degradation of HSP90 client proteins (EGFR, AKT, C-RAF and CDK4) via proteasomal pathway. Amazingly, coincident with the molecular mechanism, Y306zh also inhibits the proliferation of PC cells through G2/M phase arrest, but appears to be totally insensitive to normal mammalian cells. Furthermore, Y306zh effectively inhibits tumor growth of Mia-paca2 xenograft mice without any obvious effect on body weight.
Conclusions: Y306zh, a novel HSP90 inhibitor, interrupts ATP binding to HSP90 and disrupts HSP90-p23 interaction, and eventually inhibits the growth of PC cells.
Export Options
About this article
Cite this article as:
Xue Nina, Jin Jing, Liu Di, Yan Rui, Zhang Sen, Yu Xiaoming and Chen Xiaoguang, Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways, Current Cancer Drug Targets 2014; 14 (7) . https://dx.doi.org/10.2174/1568009614666140908101523
DOI https://dx.doi.org/10.2174/1568009614666140908101523 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease
CNS & Neurological Disorders - Drug Targets miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Calix[n]arenes as Goldmines for the Development of Chemical Entities of Pharmaceutical Interest
Current Pharmaceutical Design Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine CuAAC Click Chemistry Accelerates the Discovery of Novel Chemical Scaffolds as Promising Protein Tyrosine Phosphatases Inhibitors
Current Medicinal Chemistry Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Specialisation of the Tropomyosin Composition of Actin Filaments Provides New Potential Targets for Chemotherapy
Current Cancer Drug Targets Transcriptome Analysis of FEN1 Knockdown HEK293T Cell Strain Reveals Alteration in Nucleic Acid Metabolism, Virus Infection, Cell Morphogenesis and Cancer Development
Combinatorial Chemistry & High Throughput Screening The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery
Current Drug Targets Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Biopharmaceutic Classification System: A Scientific Framework for Pharmacokinetic Optimization in Drug Research
Current Drug Metabolism Current and New Strategies for the Delivery of Antiseptic Agents
Current Drug Delivery TLR7/9 Antagonists as Therapeutics for Immune-Mediated Inflammatory Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo
Anti-Cancer Agents in Medicinal Chemistry Ion-Pair Reversed-Phase Denaturing HPLC-Based Biotechnology as a Tool for Genetic Analysis
Current Pharmaceutical Analysis Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry